MBX Biosciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-37.1M | $-23.5M | $-21.6M | $-19.4M | $-23.9M | $-18.1M | $-15.9M | $-12.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $100.0K | $64.0K | $100.0K | $100.0K | $77.0K | $100.0K | $100.0K | $48.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $5.5M | — | — | $1.8M | — | — | $1.6M |
| Net Cash from Operating Activities | $-22.6M | $-20.2M | $-21.5M | $-17.4M | $-22.7M | $-14.7M | $-13.3M | $-10.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $901.0K | $437.0K | $399.0K | $707.0K | $30.0K | $57.0K | $452.0K | $273.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-97.1M | — | — | $3.2M | — | — | $15.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $87.4M | — | — | $4.0K | — | — | $183.0K |
| Net Change in Cash | — | $-29.9M | — | — | $-19.4M | — | — | $4.9M |
| Free Cash Flow | $-23.5M | $-20.6M | $-21.9M | $-18.1M | $-22.7M | $-14.7M | $-13.7M | $-11.0M |